Welcome to our dedicated page for Capricor Therapeutics news (Ticker: CAPR), a resource for investors and traders seeking the latest updates and insights on Capricor Therapeutics stock.
Capricor Therapeutics Inc (NASDAQ: CAPR) generates news primarily around its development of cell and exosome-based therapeutics for rare diseases, with a strong focus on Duchenne muscular dystrophy (DMD). The company’s announcements frequently highlight clinical trial milestones for its lead investigational therapy, Deramiocel (CAP-1002), as well as updates on its StealthX™ exosome platform.
Investors and followers of CAPR news can expect detailed coverage of clinical trial results and regulatory interactions. Recent communications include positive topline results from the pivotal Phase 3 HOPE-3 study of Deramiocel in DMD, information on primary and secondary endpoints such as Performance of Upper Limb (PUL v2.0) and left ventricular ejection fraction, and commentary from clinical investigators. Capricor also reports on its engagement with the U.S. Food and Drug Administration, including a Complete Response Letter for its Biologics License Application and subsequent Type A meeting to align on the role of HOPE-3 data in the regulatory pathway.
News items also cover corporate and financial developments, such as quarterly financial results, public offerings of common stock, and manufacturing readiness at the company’s GMP facility in San Diego, California. In addition, Capricor issues updates on scientific publications and conference presentations, including peer-reviewed work describing Deramiocel’s mechanism of action and data on scalable loading of therapeutic oligonucleotides into exosomes.
For those tracking CAPR, this news feed provides a centralized view of clinical, regulatory, scientific and financing updates directly related to Capricor’s programs. Regular review of these items can help readers follow the progress of Deramiocel in DMD, developments in the StealthX™ platform, and key corporate decisions that shape the company’s therapeutic pipeline.
Capricor Therapeutics announced promising results from its StealthX™ exosome platform, demonstrating the ability to induce long-lasting immunity against multiple SARS-CoV-2 proteins. The preclinical study published in bioRxiv highlights the potential of two vaccine candidates-STX-S and STX-N-to generate a strong immune response with minimal protein dosage, eliminating the need for adjuvants. This development supports the viability of StealthX™ as a versatile vaccine platform, enhancing prospects for future therapies against infectious diseases.
Capricor Therapeutics (NASDAQ: CAPR) reported progress in the HOPE-3 Phase 3 clinical trial of CAP-1002 for Duchenne Muscular Dystrophy (DMD), alongside significant one-year results from the HOPE-2 study showing improved muscle function. The third-quarter financials reveal revenues of $1.6 million, driven by a $30 million payment from Nippon Shinyaku, while net loss increased to $6.4 million. With cash reserves of $46.6 million, Capricor anticipates funding through Q2 2024. The company is also advancing its StealthX™ platform for COVID-19 vaccines and exploring global partnerships.
Capricor Therapeutics (NASDAQ: CAPR) will announce its third-quarter financial results for the period ending September 30, 2022, after market close on November 10, 2022. Following the release, management will hold a webcast and conference call at 4:30 p.m. ET. The company is focused on developing innovative cell and exosome-based therapeutics for various diseases, with its lead candidate, CAP-1002, in late-stage clinical development for Duchenne muscular dystrophy.
Capricor Therapeutics (NASDAQ: CAPR) announced the presentation of one-year safety and efficacy results from its HOPE-2 open-label extension study for CAP-1002, targeting Duchenne muscular dystrophy (DMD). The findings will be showcased during the World Muscle Society Congress from October 11-15, 2022, in Halifax, Canada. Linda Marbán, CEO, expressed pride in sharing this data to enhance awareness of DMD. The study's poster presentation is scheduled for October 14, 2022, highlighting a new treatment approach for muscle pathogenesis.
Capricor Therapeutics (NASDAQ: CAPR) announced its participation in upcoming investor conferences in September 2022. The company will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 13, 2022, from 1:30 - 2:00 p.m. ET, which includes a presentation and one-on-one meetings. Additionally, Capricor will be featured in a panel at the Cantor Fitzgerald Cell & Genetics Medicines Conference on September 15, 2022. The events will be accessible via webcast, with presentations archived on Capricor's website.
Capricor Therapeutics (NASDAQ: CAPR) has initiated the pivotal Phase 3 HOPE-3 clinical trial for CAP-1002, targeting patients with late-stage Duchenne Muscular Dystrophy (DMD). Positive results from the HOPE-2 open label extension study showcase significant improvements in muscle function. The company is pursuing FDA discussions for CAP-1002's development. Financially, Capricor reported a net loss of $7.1 million for Q2 2022, but has sufficient cash to fund operations into Q2 2024. A partnership with Nippon Shinyaku supports HOPE-3 with a $30 million upfront payment.
Capricor Therapeutics (NASDAQ: CAPR) announces it will release its financial results for the second quarter ended June 30, 2022, after market close on August 10, 2022. A conference call will be held at 4:30 p.m. ET the same day to discuss the results and provide a corporate update. Capricor focuses on developing cell and exosome-based therapeutics, particularly its lead candidate, CAP-1002, for treating Duchenne muscular dystrophy. More details can be found at capricor.com.
Capricor Therapeutics (NASDAQ: CAPR) has announced the start of patient dosing in the HOPE-3 Phase 3 clinical trial for CAP-1002, a cell therapy aimed at treating late-stage Duchenne muscular dystrophy (DMD). This randomized, double-blind, placebo-controlled study is set to enroll about 70 patients in the U.S. Positive results from the earlier HOPE-2 trial suggested CAP-1002 could slow the loss of upper limb function by up to 70%. A partnership with Nippon Shinyaku Co., Ltd. will support this trial's funding, while CAP-1002 holds regulatory designations that may facilitate its path to market approval.
Capricor Therapeutics (NASDAQ: CAPR) announces positive one-year results from its HOPE-2 open label extension study for CAP-1002 in non-ambulant patients with Duchenne muscular dystrophy (DMD). The study met its primary endpoint, showing significant improvements in the Performance of the Upper Limb (PUL 2.0) scale (p=0.02). CAP-1002 was administered to 20 original patients, 12 of whom completed the year-long follow-up. The FDA has granted CAP-1002 RMAT and Orphan Drug Designation. Capricor plans to present these findings to the FDA while currently conducting a Phase 3 trial (HOPE-3).
Capricor Therapeutics (NASDAQ: CAPR) announced it will present one-year results from its HOPE-2 study on June 25, 2022, at the PPMD Annual Conference in Scottsdale, Arizona. Dr. Linda Marbán will lead a late-breaking session at 5:05 p.m. MT, sharing safety and efficacy results for their lead asset CAP-1002, aimed at treating Duchenne muscular dystrophy (DMD). The conference, the largest international event for DMD research, will occur from June 22-26, 2022, with an option for virtual attendance.